Intera Atlas
Run match
Sites / Celerion
Is this you?

Request access for Celerion with your @celerion.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Celerion

Unclaimed profile

SMO · Lincoln, Nebraska · ~200+ beds US (Lincoln); 650+ beds globally across multiple locations sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 8Lift (cardio sample) 0.24Recruit soph 0.43
Quality Scorecard (1–100)
Overall66Recruit29Ops82Sponsor87Ther73

Performance (observed)

Historical trials
423
Completed
386
Terminated/Withdrawn
13
Completion rate
97%
Active now
22
Phase 2
19
Phase 3
5
Realized enrollment
22,696
First study year
2007
Years active
19
Match confidence
high
Enrollment velocity (inf)
1,195

Therapeutic

Areas
Clinical pharmacology, Phase I-IIb studies, SAD/MAD, FIH, cardiovascular safety (TQT), ADME, NDA-enabling studies, CNS, analgesia, abuse liability, sleep, diabetes, obesity, vaccine, device studies
Specialties
Early-phase clinical research; Phase I, bioanalysis, ADME studies
Breadth (conditions)
153
Languages
English + Spanish (detected)
States
NE, plus international

Recruitment (web observed)

Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Strong; 50+ years expertise, 6000+ studies, bioanalysis content
Capability notes
High - volunteer recruitment emphasized; 'unique rapid recruitment processes and technology' mentioned

Relationships

Sponsors
Merck Sharp & Dohme LLC; Takeda; Janssen Research & Development, LLC; Vertex Pharmaceuticals Incorporated; Incyte Corporation; Philip Morris Products S.A.
CROs
KCRN Research, LLC
Owner / parent
Founded 2010; THL (majority investment) April 2026
Acquisitions
None identified
Expansion
Global network: Lincoln NE, Phoenix AZ, Belfast UK, Zurich Switzerland; Zurich lab expansion 2026
Recent hiring
Y; expanding Zurich lab (2026)

Capacity & people

Investigators
—
Coordinators
—
CEO
Susan Thornton, Ph.D. (Founder)
VP Clinical Ops
Phil Bach (EVP, Global Clinical Research; VP since 2010)
VP Site Ops
Unknown
VP Recruitment
Phil Bach (handles innovation/recruitment tech)
Emails
Unknown

Tech & DCT

CTMS
Veeva CDMS (primary)
eSource
Yes
Builds tech
Technology-forward with automation emphasis
Home visits
N
DCT / decentralized
N; in-patient Phase I focus
Tech stack
Advanced processes, top-tier project management, real-time visibility, data integrity systems; emphasis on technology and automation
Recruiting visible
Y

Notes

Excellent Intera fit: Founder-led (Susan Thornton) early-phase CRO with 650+ global beds, 200+ US beds, recently PE-backed by THL (April 2026). Explicitly mentions 'unique rapid recruitment processes and technology' suggesting innovation in patient acquisition. 50+ years expertise in early clinical research. Multi-site network capability, founder-driven culture, growth-focused post-PE investment. Broad therapeutic areas covering high-volume opportunities (diabetes, obesity, vaccines). Technology-forward with emphasis on automation. Well-positioned for Intera's patient recruitment coordination platform.

Recommendation features (sample indication)

Ind fit 0.42Liftability 0.24Overall66

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.